ovarian cancer

From the Field

Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer

05/19/2022

Robert Reid, MD

Yiqiong Xie, PhD, MPH

Junxin Shi, PhD

Katrine L Wallace, PhD

Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.

Dr Wallace and colleagues...

05/19/2022

Journal of Clinical Pathways

News

Cost-Sharing Patterns for PARP Inhibitor Therapy in Ovarian Cancer

02/12/2021

Journal of Clinical Pathways

News

Total and Out-of-Pocket Costs of PARP Inhibitor Therapy for Ovarian Cancer

01/21/2021

Journal of Clinical Pathways

News

Rucaparib Improves PFS Over Chemo for Relapsed Ovarian Cancer

12/29/2020

Journal of Clinical Pathways

ENGAGING EXPERTS

Ovarian Cancer Maintenance: PRIMA, PAOLA-1, VELIA, and Others

06/05/2020

Michael Birrer, MD, PhD, director of the Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, discusses the latest PARP inhibitor indications for frontline maintenance in ovarian cancer, as well as the...

Michael Birrer, MD, PhD,...

06/05/2020

Journal of Clinical Pathways

Research in Review

Neoadjuvant Chemotherapy May Be Optimal for Stage IV Ovarian Cancer

09/15/2016

JCP Editors

Primary cytoreductive surgery (PCS) may improve survival for patients with stage III ovarian cancer, while neoadjuvant chemotherapy may be the optimal treatment for patients with stage IV disease, reported...

...

09/15/2016

Journal of Clinical Pathways

Research in Review

HOX Expression an Indicator of Survival in Patients With Ovarian Cancer

07/01/2016

JCP Editors

A study out of the United Kingdom has identified a key gene signature in ovarian cancer that may be useful in predicting survival. The HOX gene family is largely responsible for the rapid cell division seen in...

A...

07/01/2016

Journal of Clinical Pathways

Non-Platinum-Based Chemo May Worsen Survival in Ovarian Cancer

06/10/2016

JCP Editors

Prolonging platinum-free interval (PFI) by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer, according to clinical trial results presented at...

...

06/10/2016

Journal of Clinical Pathways

Research in Review

05/06/2016

JCP Editors

A look at more than 10 years of data has shown that many patients with ovarian cancer covered by Medicare are not receiving treatment consistent with National Comprehensive Cancer Network (NCCN) recommendations,...

...

05/06/2016

Journal of Clinical Pathways

Research in Review

Are Patients Receiving Optimal Ovarian Cancer Treatment?

08/27/2015

JCP Editors

A study recently published in the Journal of Clinical Oncology found that fewer than 50% of eligible patients with debulked Stage 3 ovarian cancer treated at National Comprehensive Cancer Network (NCCN) centers have...

A...

08/27/2015

Journal of Clinical Pathways